HOUSTON, Oct. 21, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announces
it will host a webcast to present the company's interim keloid and
hypertrophic scar proof-of-concept ("POC") trial data on
October 25, 2019 at 5:30 p.m. ET.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
The fibrotic scar POC trial data will be presented to the
medical community October 24, 2019,
at the American Society for Dermatologic Surgery ("ASDS"). A press
release will make the data broadly available at 8:00 a.m. ET on October
25, 2019, and a follow-up webcast will be held October 25, 2019, at 5:30
p.m. ET.
"We will be presenting the results from the initial follow-up
visit of our clinical trial to attendees at the American
Society for Dermatologic Surgery ("ASDS") Annual Meeting on
October 24, 2019," stated
Christopher Capelli, MD, founder,
President and CEO of Soliton. "We look forward to being able to
share these results with our shareholders and all interested
parties through this live webcast and further explain why we
believe success with keloid and hypertrophic scars could
potentially extend to other fibrotic disorders such as capsular
contracture, Peyronie's Disease, and even liver fibrosis."
Interested parties can access the webcast on the Company's
website under the Investors section at http://ir.soliton.com.
Keloid and hypertrophic scars (also referred to as fibrotic
scars) represent wound healing gone awry. A typical example
would be a post-surgical scar that grows beyond its
boundaries. Existing published research suggests that factors
relating to the wound-healing environment (including extracellular
matrix stiffness and tension at the boundary of the scar) can cause
fibroblasts to become stuck in a hyper-productive loop, unable to
stop the production of collagen that leads to the thickened, raised
and dense structures often associated with these fibrotic
scars.
The American Osteopathic College of Dermatology estimates that
keloids affect around 10 percent of people,
whereas hypertrophic scars are more common. Keloid
scars are more prevalent among populations with darker skin
pigmentation. Hypertrophic scars affect men and women
from any racial group equally, with people between the
ages of 10 and 30 years old being the most likely to be
affected.
Grand View Research estimates the global market for keloid and
hypertrophic scars may reach $10.2
billion by 2025. There are few treatment options available
for fibrotic scars, which in addition to being disfiguring, can
also cause significant discomfort. Currently, the most common
treatment is the direct injection of steroids into the scar,
however this can require multiple injections and may not be a
permanent solution.
Soliton's technology for the treatment of keloid and
hypertrophic scars has not been cleared by the FDA and is not yet
available for sale in the United
States.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction of
keloid and hypertrophic scars, the ability for Soliton to receive
FDA clearance for these additional indications and the ability of
Soliton to pursue treatment of other fibrotic disorders. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
|
Joe Dorame, Joe
Diaz & Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
|
soly@lythampartners.com
|
View original
content:http://www.prnewswire.com/news-releases/soliton-to-announce-keloid-trial-data-on-october-25-2019-and-host-webcast-at-530pm-et-to-discuss-results-300941761.html
SOURCE Soliton, Inc.